Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Genetic Tools Improve Breast Cancer Risk Prediction for African American Women

By LabMedica International staff writers
Posted on 09 Feb 2026

Despite advances in genetic testing, breast cancer death rates remain disproportionately high among women of African ancestry. More...

Existing risk prediction tools often fail to accurately assess risk in this group, contributing to later diagnoses and poorer outcomes. Greater genetic diversity and higher rates of aggressive tumor subtypes further complicate early detection. Researchers have now developed improved genetic risk models that significantly enhance breast cancer risk prediction in women of African ancestry.

In the study led by the University of Chicago Medicine (Chicago, IL, USA) researchers used genetic data from more than 36,000 women to develop new polygenic risk score (PRS) models specifically for women of African ancestry. The models were built using data from the African Ancestry Breast Cancer Genetics Consortium, which includes participants from the U.S., the Caribbean, and Sub-Saharan Africa.

Polygenic risk scores estimate cancer risk by analyzing multiple single-nucleotide polymorphisms (SNPs) across the genome. Because African ancestry populations have greater genetic diversity, models trained primarily on European data often miss key risk signals. The researchers created separate PRS models for overall breast cancer, estrogen receptor–positive cancer, estrogen receptor–negative cancer, and triple-negative breast cancer, ensuring more precise risk stratification.

The new models showed significantly improved predictive performance, with area under the curve (AUC) values ranging from 0.61 to 0.64, compared with 0.56 to 0.58 for earlier models. The research, published in Nature Genetics, also demonstrated that simplified models using fewer genetic markers maintained similar accuracy. Validation across multiple independent datasets confirmed the robustness of the approach.

The findings suggest that women identified as high risk could benefit from earlier and more frequent screening, potentially starting in their early 30s. Combining PRS results with family history further strengthened risk prediction, identifying individuals with lifetime breast cancer risks exceeding 50%. Researchers emphasize that future work will refine these models for broader African populations and support more equitable cancer prevention strategies.

“With improved risk prediction, doctors can start screening earlier for women at higher risk, tailor care based on a woman’s specific risk profile and catch the cancers sooner,” said Professor Dezheng Huo, PhD, senior author of the study.

Related Links:
University of Chicago Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automated Urinalysis Solution
UN-9000
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.